9 jan 2023
JPMorgan presentation
Potential for indication expansion: Literature reports of CAIX expression
Glioblastoma Multiforme
Nasopharyngeal Carcinoma
Non-Small Cell Lung Cancer
Hepatocellular Carcinoma
Gastric Cancer
Pancreatic Ductal Adenocarcinoma
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Esophageal Cancer
Small Cell Lung Cancer
Cholangio-carcinoma
Soft Tissue Sarcoma
Epithelial Ovarian Cancer
Colorectal Cancer
- Forums
- ASX - By Stock
- TLX
- Ann: Phase II study for indication expansion of TLX250-CDx doses
Ann: Phase II study for indication expansion of TLX250-CDx doses, page-7
-
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$18.27 |
Change
0.120(0.66%) |
Mkt cap ! $6.122B |
Open | High | Low | Value | Volume |
$18.00 | $18.31 | $17.92 | $10.03M | 554.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 1177 | $18.26 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.27 | 491 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 537 | 18.280 |
15 | 9550 | 18.270 |
13 | 1885 | 18.260 |
10 | 1271 | 18.250 |
7 | 774 | 18.240 |
Price($) | Vol. | No. |
---|---|---|
18.290 | 777 | 8 |
18.300 | 868 | 8 |
18.310 | 1000 | 6 |
18.320 | 1100 | 12 |
18.330 | 713 | 8 |
Last trade - 13.54pm 11/09/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |